Maxim Group set a $5.00 price target on Soligenix Inc. (NASDAQ:SNGX) in a research note issued to investors on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $11.00 price objective on shares of Soligenix in a research report on Thursday, September 21st.

Soligenix (SNGX) traded up $0.11 during mid-day trading on Tuesday, reaching $2.05. 45,356 shares of the company were exchanged, compared to its average volume of 97,852. Soligenix has a one year low of $1.74 and a one year high of $5.08.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Friday, August 11th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.09). Soligenix had a negative net margin of 86.15% and a negative return on equity of 129.88%. The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $1.43 million. analysts anticipate that Soligenix will post -1.52 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Analysts Give Soligenix Inc. (SNGX) a $5.00 Price Target” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.